Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

查看全文 作　　者：Xiaohan [1]Zhou;Kun [1]Shi;Ying [1]Hao;Chengli [1]Yang;Ruoyu [1]Zha;Cheng [1]Yi;Zhiyong [1]Qian

机构地区：[1]Department of Medical Oncology,State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,West China Medical School,Sichuan University,and Collaborative Innovation Center for Biotherapy,Chengdu 610041,China

出　　处：《Asian Journal of Pharmaceutical Sciences》索引2020年第15卷第1期,共16页

基　　金：financially supported by the National Natural Science Foundation (31525009 and 31771096);The National Key Research and Development Program of China (2017YFC1103502);Sichuan Innovative Research Team Program for Young Scientists (2016TD0004);Distinguished Young Scholars of Sichuan University (2011SCU04B18);1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University. 摘　　要：Oral tyrosine kinase inhibitors(TKIs) against epidermal growth factor receptor(EGFR) family have been introduced into the clinic to treat human malignancies for decades. Despite superior properties of EGFR-TKIs as small molecule targeted drugs, their applications are still restricted due to their low solubility, capricious oral bioavailability, large requirement of daily dose, high binding tendency to plasma albumin and initial/acquired drug resistance. Nanotechnology is a promising tool to improve efficacy of these drugs. Through non-oral routes. Various nanotechnology-based delivery approaches have been developed for providing efficient delivery of EGFR-TKIs with a better pharmacokinetic profile and tissue-targeting ability. This review aims to indicate the advantage of nanocarriers for EGFR-TKIs delivery. 关键词：NANOTECHNOLOGY EGFR TYROSINE KINASE INHIBITOR Cancer therapy

相关文献

参考文献（123）
引证文献（2）
耦合文献（0）

参考文献(123)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

参考文献(123)

引证文献(2)

用户提示